Zhitong Finance App News, Huayu Bio-B (02396) issued an announcement. The phase II clinical trial of Pro-101-2 developed by the company and used to treat diabetic foot ulcers has recently completed the enrollment of all patients. Pro-101-2 is one of our core products. This clinical trial is a randomized, double-blind, placebo-controlled study to further evaluate the efficacy and safety of recombinant human platelet-derived growth factor (rhPDGF-bb) gel in treating diabetic foot ulcers, and to provide key parameters for the design of subsequent phase III clinical trials in a large number of enrolled subjects. The completion of the phase II clinical trial of PRO-101-2 is another major development advance in the company's research and development in the field of diabetic foot ulcer treatment.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.